Date: Saturday, June 11, 2016
Session Name: Poster Session A: Kidney: Acute Cellular Rejection
Session Time: 5:30pm-7:30pm
Presentation Time: 5:30pm-7:30pm
Location: Halls C&D
MicroRNAs (miRs) have been reported to play a role in immune system response. The results of several clinical trials have suggested that these molecules might be used as biomarkers to predict the risk of rejection and allograft outcome. Most studies have shown an association between elevated urinary CXCL-10 chemokine levels with ongoing acute rejection (AR) and the prediction of graft fibrosis and later allograft failure.
Sixty de novo renal transplant recipients were recruited from 3 European centers. All patients were treated with Prograf, Myfenax and corticosteroids. Urinary miR (miR-155-5p, miR-142-3p, miR-210-3p) expression was evaluated by quantitative RT-PCR ([Delta]Ct) and urinary CXCL-10 production was tested by ELISA post-transplantation (1stweek, 1stmonth, 2ndmonth, 3rdmonth and 6thmonth).
Eight patients experienced biopsy-proven AR (13.3%), all of them before the 1st month post-transplantation except one who rejected at 6 months. Patients who rejected showed a significant increase in urinary expression of CXCL-10 (1stweek:229.6±73.4 vs 66±4pg/ml, P=0.001; 1st month:140.4±52.3 vs 24.6±23.3pg/ml,P=0.001);miR-155 (1stweek:2.80±1.25 vs 0.035±0.01, P=0.002; 1st month:1.06±0.91 vs 0.17±0.09,P=0.01) and miR-142 (1stweek:1.13±0.72 vs 0.58±0.23, P=0.002; 1st month:7.19±2.01 vs 2.14±1.05,P=0.002) and a decrease in miR-210 (1stweek:0.07±0.05 vs 0.21±0.13, P=0.04; 1st month:0.008±0.001 vs 0.17±0.11,P=0.02). No significant differences were observed between rejectors and non-rejectors in donor and recipient age, cold ischemia time, immunosuppressive therapy and drug exposure.
miR-210 and CXCL-10 correlated with glomerular filtration rate overtime and a normalization of levels of both biomarkers was seen after successful graft function recovery.
In summary, monitoring urinary levels of these miRs and CXCL-10 have the potential to act as specific biomarkers to help predict the risk of rejection and long-term graft function. However, prospective data from large cohorts in multicenter clinical trials are required to qualify the clinical utility of these biomarkers.
CITATION INFORMATION: Millan O, Budde K, Sommerer C, Aliart I, Rissling O, Bardaji B, Matz M, Zeier M, Silva I, Guirado L, Brunet M. Urinary Expression of miRNA-155, miRNA-210, miRNA-142 and CXCL-10 Production Predicts the Risk of Acute Rejection and Graft Outcome in Renal Transplant Recipients. Am J Transplant. 2016;16 (suppl 3).
To cite this abstract in AMA style:Millan O, Budde K, Sommerer C, Aliart I, Rissling O, Bardaji B, Matz M, Zeier M, Silva I, Guirado L, Brunet M. Urinary Expression of miRNA-155, miRNA-210, miRNA-142 and CXCL-10 Production Predicts the Risk of Acute Rejection and Graft Outcome in Renal Transplant Recipients. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/urinary-expression-of-mirna-155-mirna-210-mirna-142-and-cxcl-10-production-predicts-the-risk-of-acute-rejection-and-graft-outcome-in-renal-transplant-recipients/. Accessed April 10, 2020.
« Back to 2016 American Transplant Congress